TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

NCT04485013 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: TTX-080
DRUG: TTX-080
DRUG: pembrolizumab
DRUG: cetuximab
DRUG: FOLFIRI
DRUG: cetuximab
DRUG: TTX-080

Sponsor

Tizona Therapeutics, Inc